SavedAdd your journal

Journals / Van Tıp Dergisi / 2012 / Cilt: 19 - Sayı: 4

Identification and antifungal susceptibilities of candida species isolated from various clinical specimens

Çeşitli klinik örneklerden izole edilen candida kökenlerinin identifikasyonu ve antifungal duyarlılıklarının araştırılması

Yasemin BAYRAM
Bilge GÜLTEPE
Suat ÖZLÜK
HÜSEYİN GÜDÜCÜOĞLU
Pages
177–181
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: This study examined the presence of variety of yeast species and their in vitro susceptibility patterns to antifungal agents in different clinical specimens.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aims of this study were to identify the species of 38 yeast strain isolated from various clinical specimens and determine their antifungal susceptibility patterns.
📊
Key Findings & Data:Methods: We identified the species of the yeast with API ID 32 C kit, and determined the in vitro antifungal susceptibility to flucytosine, amphotericin B, fluconasole, itraconazole and voriconasole with API ATB Fungus kit.
💡
Conclusion & Impact:Conclusion: This study examined the presence of variety of yeast species and their in vitro susceptibility patterns to antifungal agents in different clinical specimens.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aims of this study were to identify the species of 38 yeast strain isolated from various clinical specimens and determine their antifungal susceptibility patterns. Methods: We identified the species of the yeast with API ID 32 C kit, and determined the in vitro antifungal susceptibility to flucytosine, amphotericin B, fluconasole, itraconazole and voriconasole with API ATB Fungus kit. Results: A total of 153 yeast sample is examined. Candida albicans and non-albicans species were isolated in 112 examples. The isolated 31 strains (28%) were from urine, 45 strains (40%) were from blood, 11 strains (9%) were from wounds, 5 strains (5%) were from abscesses, 8 strains (7%) were from respiratory tract samples, 4 strains (% 4) were from sputum, 3 strains (3%) were from ascites fluid, 4 strains (3%) were from vagina, 1 strain (1%) was isolated from cerebrospinal fluid material. A total of 112 Candida species were isolated and these consisted of 56(50%) C. albicans, 7(6%) C.glabrata, 27(24%) C. parapsilosis, 7(6%) C. tropicalis, 3(2%) C.guillermondii, 12(11%) C. Kefyr species. The resistance rates determined by exam with ATB Fungus 3 kit for flucytosine, amphotericin, fluconasole, itraconasole and voriconasole were as follows; 5 (4%), 3 (3%), 43 (38%), 55 (49%) and 48 (43%) respectively. Conclusion: This study examined the presence of variety of yeast species and their in vitro susceptibility patterns to antifungal agents in different clinical specimens.

Özet

Amaç: Bu çalışmada, çeşitli klinik örneklerden izole edilen 38 maya suşunun tür tanımlaması ve antifungal duyarlılıklarının belirlenmesi amaçlanmıştır. Yöntem: Mayalar API ID 32 C kiti ile tiplendirilmiş, API ATB Fungus kiti ile de flusitozin, amfoterisin B, flucanazol, ıtrakanazol’e ve vorikonazol karşı in vitro antifungal duyarlılıkları saptanmıştır. Bulgular: Toplam 153 örnek maya mantarı açısından incelendiğinde; 112 örnekte albicans ve non-albicans olmak üzere candida türleri izole edilmiştir. Suşların 31(%28)’i idrar, 45(%40)’i kan, 11(%9)’i yara, 5(%5)’i apse, 8(%7)’i solunum materyali, 4(%4)ü balgam, 3(%3)’ü parasentez, 4(%3)’ü vagen, 1(%1)’i BOS materyalinden izole edilmiştir. Toplam üretilen 112 candida türlerinin 56(% 50)’si C. albicans, 7(%6)’i C. glabrata, 27(%24 )’si C.parapsilosis, 7(%6)’si C.tropicalis, 3(%2)’ü C.guillermondii, 12(%11)’u C.kefyr’den oluşmaktadır. ATB Fungus 3 kitiyle yapılan incelemede direnç oranları şu şekilde saptanmıştır; flusitozin’e 5(%4), amfoterisin B’ye 3(%3), flukonazol’e 43(%38), ıtrakonazol’e 55(%49) ve varikonazol’e 48(%43) oranında direnç saptanmıştır. Sonuç: Candida infeksiyonlarının tedavisinde etkenlerin tür tanımlaması ve antifungal duyarlılıklarının saptanması gerektiği anlaşılmıştır.

🔖

Cite This Article

BAYRAM, Y., GÜLTEPE, B., ÖZLÜK, S., GÜDÜCÜOĞLU, H. (2012). Identification and antifungal susceptibilities of candida species isolated from various clinical specimens. Van Tıp Dergisi, Cilt: 19 - Sayı: 4, 177–181. https://ajindex.com/articles/334221

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Hazen KC, Howell SA. Candida, Cryptococcus, and other yeasts of medical importance, “Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA: Manual of Clinical Microbiology, 9th edition” kitabında s.1762- 1788, ASM Press,
  2. Washington D.C. (2007). 2. Saraçlı MA. Mantar Hastalıklarının Patogenezi, Murray P.R, Rosenthal K.S, Phaller M.A, Tıbbi Mikrobiyoloji (Çeviri editörü: Ahmet Başustaoğlu), s. 679-688,
  3. Atlas Kitapçılık, Ankara, 2010. 3. Emel Tümbay, Candida türleri, Ustaçelebi Ş, Mutku G, İmir T, Cengiz T, Tümbay E, Mete Ö, Temel ve Klinik Mikrobiyoloji, s. 1081- 1086, Güneş Kitabevi, Ankara, 1999. 4. Gültekin B, Eyigör M, Telli M, Aksoy M, Neriman Aydın N. Yedi Yıllık Dönemde Kan Kültürlerinden İzole Edilen Candıda Türlerinin Retrospektif Olarak İncelenmesi, ANKEM Derg 2010; 24(4):202-208. 5. Winn WC, Allen SD, Janda WM, Koneman EW, Procop GW, Schreckenberger P.C., ety al. Mycology. In: Koneman’s Color Atlas and Textbook of Diagnostic Microbiology 6th ed, pp: 1151-1243,
  4. Philadelphia, Pa, Lippincott Williams & Wilkins, 2006. 6. Yıldıran ŞT. Mantar Hastalıklarının Tanısı, Murray P.R, Rosenthal K.S, Phaller M.A, Tıbbi Mikrobiyoloji (Çeviri editörü: Ahmet Başustaoğlu), s. 689-699,
  5. Atlas Kitapçılık, Ankara, 2010. 7. Ener B. Candida infeksiyonlarında epidemiyoloji ve laboratuvar tanı, ANKEM Derg 2008; 22:264-269. 8. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem, Clin Microbiol Rev 2007; 20(1):133- 163. 9. Zer Y, Balci I, Meriç G. Identification and antifungal susceptibility of Candida isolated from intensive care unit patients. New Microbiol 2002; 25(4):489-494. 10. Comert F, Kulah C, Aktas E, Eroglu O, Ozlu N. Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period. Mycoses 2007; 50(1):52-57. 11. Ergon MC, Yücesoy M. Evaluation of species distribution of yeasts isolated from intensive care units during the four years period, Microbiyol Bul 2005; 39:309-318. 12. Ekşi F, Bayram A, Karslıgil T, Balcı İ. Çeşitli klinik örneklerden soyutlanan Candida’ların tür dağılımı, Türk Mikrobiyol Cem Derg 2007; 37(1):26-30. 13. Özkan S, Kaynak F, Abbasoğlu U, Gür D. Çocuk hastalardan izole edilen candida türlerinin çeşitli antifungallere duyarlılıklarının Klinik Çalışma araştırılması, Türk Mikrobiyol Cem Derg 2004; 34:253-256. 14. Adiloğlu AK, Şirin MC, Cicioğlu Arıdoğan B, Can R, Demirci M. Çeşitli klinik örneklerden izole edilen Candid